FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach

CNBC June 7, 2024
Annika Kim Constantino

Key Points

– The Food and Drug Administration expanded the approval of GSK’s respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus.

– The agency first approved GSK’s jab in May 2023 for patients 60 and above, who are more vulnerable to severe cases of the virus.

– The FDA’s expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.

The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus....

Today's Sponsors

Today's Sponsor